Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 12/11/23
End: 11/30/26
Due: 11/30/27
Phase: N/A
Priority: Normal
Start: 04/15/22
End: 01/31/40
Due: 01/31/41
Phase: N/A
Priority: Normal
Start: 12/16/21
End: 01/31/27
Due: 01/31/28
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant | NCT05984199 | Vor Biopharma | user2@example.com | None | 2023-12-11 | 2026-11-30 | 2027-11-30 | - | - | 2025-07-14 |
| A Long-term Follow-up Study of Patients Who Received VOR33 | NCT05309733 | Vor Biopharma | user2@example.com | None | 2022-04-15 | 2040-01-31 | 2041-01-31 | - | - | 2025-07-14 |
| Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS | NCT04849910 | Vor Biopharma | user2@example.com | None | 2021-12-16 | 2027-01-31 | 2028-01-31 | - | - | 2025-07-14 |